LONDON (Reuters) – Novo Nordisk will begin a new late-stage trial of its experimental next-generation obesity drug CagriSema on Feb. 10, according to a www.clinicaltrials.gov entry.
The Danish drugmaker last month revealed disappointing results in a late-stage trial of CagriSema, wiping as much as $125 billion off its market value. It said then that it would initiate a new trial in 2025 but did not say when exactly.
The trial is estimated to end in November 2028, the entry shows. The company did not immediately respond to a request to comment.
(Reporting by Maggie Fick; Editing by Ros Russell)
Source link : https://www.medscape.com/s/viewarticle/novo-nordisks-new-cagrisema-obesity-drug-trial-begin-feb-10-2025a10002eq?src=rss
Author :
Publish date : 2025-01-30 14:42:34
Copyright for syndicated content belongs to the linked Source.